Protocol Ledger

NCT07549321 · Phase II/III · RECRUITING

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

Interventional Phase II/III clinical trial protocol NCT07549321 sponsored by Renaissance Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-30 Enrollment: 144 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07549321
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)144 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07549321
Protocol FieldVerified Registry Value
NCT IdentifierNCT07549321
Consolidated Lead SponsorRenaissance Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment144 participants (ESTIMATED)
Registered Start Date2026-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI